《LANCET,3月13日,COVID-19: delay, mitigate, and communicate》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-03-14
  • COVID-19: delay, mitigate, and communicate

    Published Online March 13, 2020 https://doi.org/10.1016/S2213-2600(20)30128-4

    On March 11, 2020, WHO declared COVID-19 a pandemicand has called for governments to take “urgent and aggressive action” to change the course of the outbreak. As of March 12, 2020, the USA has suspended all travel from 26 European countries, and Italy is the latest country to enforce widespread lockdown measures to curb the spread of the virus. Robust plans and policies to avoid the disease trajectories seen in the worst-hit countries are urgentlyneeded. These responses must be proportionate to each country’s situation and communicated in a clear and balanced way to avoid spreading fear and panic.

  • 原文来源:https://www.thelancet.com/lancet/article/S2213-2600(20)30128-4
相关报告
  • 《LANCET,3月3日,Mitigate the effects of home confinement on children during the COVID-19 outbreak》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-04
    • In response to the coronavirus disease 2019 (COVID-19) outbreak, the Chinese Government has ordered a nationwide school closure as an emergency measure to prevent spreading of the infection. Public activities are discouraged. The Ministry of Education estimates that more than 220 million children and adolescents are confined to their homes; this includes 180 million primary and secondary students and 47 million preschool children).
  • 《LANCET,3月13日,COVID-19: consider cytokine storm syndromes and immunosuppression》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-03-14
    • COVID-19: consider cytokine storm syndromes and immunosuppression Published Online March 13, 2020 https://doi.org/10.1016/S0140-6736(20)30628-0 As of March 12, 2020, coronavirus disease 2019 (COVID-19) has been confirmed in 125 048 people worldwide, carrying a mortality of approximately 3·7%,1 compared with a mortality rate of less than 1% from influenza. There is an urgent need for effective treatment. Current focus has been on the development of novel therapeutics, including antivirals and vaccines. Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome. We recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality.